Impact of 177Lu-PSMA therapy on kidney function in prostate cancer patients
Official title: 177Lu-PSMA-KiRi-trial
Run by Technical University of Munich · NCT06720532 · Data updated 2026-11-12
This study is testing how a new prostate cancer treatment affects kidney function in men with advanced prostate cancer over five years.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 100 (estimated) |
| Sponsor | Technical University of Munich Academic / other |
| Locations | 1 site (Munich) |
| Status | Recruiting |
| Started | August 5, 2024 |
| Main results expected | August 1, 2027 |
| Study ends | August 1, 2031 |
| Registry record updated | December 6, 2024 |
| Trial ID | NCT06720532 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 years with metastatic castration-resistant prostate cancer who are starting their first cycle of 177Lu-PSMA therapy.
✕Probably not a fit
Patients who are not starting 177Lu-PSMA therapy or are under 18 years old will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess how 177Lutetium-Prostate Specific Membrane Antigen (PSMA) Radioligand Therapy affects kidney function in patients with metastatic castration-resistant prostate cancer (mCRPC). It will monitor kidney function using routine markers like creatinine and cystatin C before, during, and after therapy, with follow-ups extending up to 5 years. The study will also collect additional biomarkers and patient-reported outcomes to identify risk factors for chronic kidney disease and correlate them with clinical data. A total of 100 patients will be included to ensure robust data collection and analysis.
Why it matters
Potential benefit: If successful, this study could help identify kidney function decline in prostate cancer patients undergoing treatment, leading to better management of kidney health.
How similar studies have gone: While there have been studies on kidney function in cancer therapies, this specific approach focusing on 177Lu-PSMA therapy and its renal impact is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with mCRPC starting 177Lu-PSMA RLT at the Klinikum rechts der Isar at the time of therapy initiation (1st cycle). Exclusion Criteria: * Missing or incomplete informed consent. * age below 18 years
Where it's running
-
Klinikum rechts der Isar, München, Bavaria 81675
Munich, Germany Recruiting
Study contacts
- Study coordinator: Hannah Schäfer/ Christoph Schmaderer
- Email: hannah.schaefer@mri.tum.de
- Phone: +49 - 89 4140 8383
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pedal Pump Device for Lower Extremity Edema in Hospitalized Patients
This study tests a foot-pump device to see if it is tolerable and can help reduce swelling in the legs of hospitalized patients with edema.
-
Adapting and testing PEN-Plus in Zambian primary care
Aiming to see if the PEN-Plus package can be adapted and used in two Zambian hospitals to better manage chronic diseases like heart disease, diabetes, hypertension, and sickle cell in primary care.
-
Effects of general vs spinal-epidural anesthesia on kidney transplant biomarkers
This study tests whether sevoflurane general anesthesia or combined spinal-epidural anesthesia changes markers of cellular stress and protective peptides in adults undergoing kidney transplantation.
-
Impact of a Clinical Information System on hospital outcomes for adults with chronic diseases
This study tests whether implementing a Clinical Information System helps reduce readmissions or death within 30 days after hospital discharge for adults with chronic conditions in Alberta.
-
GSK4771261 in Healthy Adults Aged 25–55 in Asia and Europe
This study tests whether GSK4771261 is safe and how it behaves in the body of healthy adults to see if it could be used safely in the future.
-
Red propolis supplementation for people with chronic kidney disease
This study tests whether taking red propolis daily for 8 weeks can reduce inflammation and oxidative stress in people with chronic kidney disease who are managed without dialysis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.